TFCP
VRTX icon

Twin Focus Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Twin Focus Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,122
Closed -$354K – 238
2023
Q1 		$354K Hold
1,122
– – 0.07% 142
2022
Q4 		$324K Hold
1,122
– – 0.07% 147
2022
Q3 		$325K Sell
1,122
-20
-2% -$5.75K 0.08% 136
2022
Q2 		$322K Sell
1,142
-22
-2% -$5.89K 0.07% 142
2022
Q1 		$304K Sell
1,164
-34
-3% -$8.07K 0.06% 160
2021
Q4 		$263K Buy
1,198
+93
+8% +$18.1K 0.05% 184
2021
Q3 		$200K Buy
1,105
+7
+0.6% +$1.37K 0.05% 182
2021
Q2 		$221K Buy
1,098
+26
+2% +$5.44K 0.05% 175
2021
Q1 		$230K Buy
1,072
+52
+5% +$11.4K 0.07% 135
2020
Q4 		$241K Buy
1,020
+40
+4% +$9.18K 0.07% 135
2020
Q3 		$267K Buy
980
+27
+3% +$7.45K 0.1% 111
2020
Q2 		$277K Sell
953
-1
-0.1% -$271 0.11% 109
2020
Q1 		$227K Buy
954
+18
+2% +$4.13K 0.1% 125
2019
Q4 		$205K Buy
+936
New +$189K 0.07% 186

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Twin Focus Capital Partners's VRTX Position: Q2 2023 in Review

Twin Focus Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 1,122 shares — an estimated $354K sold.

Twin Focus Capital Partners first reported a position in VRTX in Q4 2019 and held it in 14 quarters. The position peaked at $354K in Q1 2023. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • Twin Focus Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Twin Focus Capital Partners sold 1,122 Vertex Pharmaceuticals shares in Q2 2023, an estimated $354K.
  • Twin Focus Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 14 quarters.
  • Twin Focus Capital Partners's Vertex Pharmaceuticals position peaked at $354K in Q1 2023.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Twin Focus Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.